Circulatory concentrations of fibrinolytic species during thrombolytic therapy estimated by stirred-tank reactor analysis.
OBJECTIVE
A model for calculating the circulatory concentrations of fibrinolytic species is proposed and the findings are compared to reported values where available.


METHODS
The model uses a CSTR analysis with fourth order Runge-Kutta solution of the differential equations to determine concentration profiles of key fibrinolytic species as a function of time during fibrinolytic therapy. Concentrations of the species are also determined for various dosage regimens of streptokinase and plasminogen.


RESULTS
Data calculated by the model is in agreement with general experimental trends determined in vitro and in vivo.


CONCLUSIONS
The proposed model can be used to predict concentration profiles of key fibrinolytic species during administration of streptokinase.
Tuliani
V V
VV
Smith Kline Beecham Pharmaceuticals, Prussia, Pennsylvania 19406, USA.
O'Rear
E A
EA
D001775:Blood Circulation; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D007262:Infusions, Intravenous; D008962:Models, Theoretical; D010958:Plasminogen / Q000378:metabolism; D013300:Streptokinase / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D015912:Thrombolytic Therapy; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D005337:Fibrin; D010958:Plasminogen; D013300:Streptokinase; D005341:Fibrinolysin